A population-based cohort study of stage I–IIIA NSCLC patients diagnosed in Denmark during 2013 and 2018 reported that nearly half of the patients (46.5%) underwent EGFR testing with 8.9% identified as EGFRm+ [4]. Here, EGFR is linked to non-small cell lung carcinoma.